BRIM Biotechnology, Inc. (TPE:6885)

Market Cap	3.12B
Revenue (ttm)	433.00K
Net Income (ttm)	-347.36M
Shares Out	132.31M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,535
Average Volume	158,740
Open	22.55
Previous Close	22.45
Day's Range	21.70 - 22.55
52-Week Range	27.50 - 50.20
Beta	1.22
RSI	43.30
Earnings Date	May 13, 2025

About BRIM Biotechnology

BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 32
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6885

Financial Performance

In 2024, BRIM Biotechnology's revenue was 333,000, an increase of 270.00% compared to the previous year's 90,000. Losses were -315.47 million, -54.15% less than in 2023.